These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20815029)

  • 1. Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families.
    Balleine RL; Provan PJ; Pupo GM; Pathmanathan N; Cummings M; Farshid G; Salisbury EL; Bilous AM; Byth K; ; Mann GJ
    Genes Chromosomes Cancer; 2010 Dec; 49(12):1082-94. PubMed ID: 20815029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
    Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer susceptibility variants alter risks in familial disease.
    Latif A; Hadfield KD; Roberts SA; Shenton A; Lalloo F; Black GC; Howell A; Evans DG; Newman WG
    J Med Genet; 2010 Feb; 47(2):126-31. PubMed ID: 19617217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
    Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
    Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients.
    Didraga MA; van Beers EH; Joosse SA; Brandwijk KI; Oldenburg RA; Wessels LF; Hogervorst FB; Ligtenberg MJ; Hoogerbrugge N; Verhoef S; Devilee P; Nederlof PM
    Breast Cancer Res Treat; 2011 Nov; 130(2):425-36. PubMed ID: 21286804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
    Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
    Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
    Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
    Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease family history and modification of breast cancer risk in common BRCA2 variants.
    Seymour IJ; Casadei S; Zampiga V; Rosato S; Danesi R; Falcini F; Strada M; Morini N; Naldoni C; Paradiso A; Tommasi S; Schittulli F; Amadori D; Calistri D
    Oncol Rep; 2008 Mar; 19(3):783-6. PubMed ID: 18288416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
    Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
    Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.
    Lakhani SR; Gusterson BA; Jacquemier J; Sloane JP; Anderson TJ; van de Vijver MJ; Venter D; Freeman A; Antoniou A; McGuffog L; Smyth E; Steel CM; Haites N; Scott RJ; Goldgar D; Neuhausen S; Daly PA; Ormiston W; McManus R; Scherneck S; Ponder BA; Futreal PA; Peto J; Stoppa-Lyonnet D; Bignon YJ; Stratton MR
    Clin Cancer Res; 2000 Mar; 6(3):782-9. PubMed ID: 10741697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and pathological characterization of inherited breast cancer.
    Borg A
    Semin Cancer Biol; 2001 Oct; 11(5):375-85. PubMed ID: 11562180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
    Kataki A; Gomatos I; Pararas N; Armakolas A; Panousopoulos D; Karantzikos G; Voros D; Zografos G; Markopoulos C; Leandros E; Konstadoulakis M
    Clin Genet; 2005 Apr; 67(4):322-9. PubMed ID: 15733268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies.
    Gonzalez-Neira A; Rosa-Rosa JM; Osorio A; Gonzalez E; Southey M; Sinilnikova O; Lynch H; Oldenburg RA; van Asperen CJ; Hoogerbrugge N; Pita G; Devilee P; Goldgar D; Benitez J
    BMC Genomics; 2007 Aug; 8():299. PubMed ID: 17760956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.